Lynk Pharmaceuticals Completes Phase III AS Trial Enrollment
HANGZHOU, China, SHANGHAI & BOSTON — July 14, 2026 Lynk Pharmaceuticals Co., Ltd. has announced the successful completion of...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
HANGZHOU, China, SHANGHAI & BOSTON — July 14, 2026 Lynk Pharmaceuticals Co., Ltd. has announced the successful completion of...
VALENCIA, Calif., June 29, 2026 SetPoint Medical has announced a significant milestone in the expansion of its FDA-approved SetPoint...
NORTH CHICAGO, Ill., June 26, 2026 AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI®...
SANDWICH, UK, June 3, 2026 Levicept Ltd announced new data from its Phase 2 clinical trial of LEVI-04, a...
HORSHAM, Pennsylvania, May 28, 2026 Johnson & Johnson has secured a major regulatory milestone after the U.S. Food and...
PRINCETON, N.J., May 11, 2026 Bristol Myers Squibb announced that the European Commission has approved Sotyktu (deucravacitinib) for the...
